Health
‘Another agent in our arsenal’: Finerenone benefits extend to those with, without CVD – Healio
Among adults with chronic kidney disease and type 2 diabetes, the mineralocorticoid receptor inhibitor antagonist finerenone reduced the incidence of CV events…
Source/Disclosures
Source: Filippatos G, et al. LBS.07: Randomized trials — brain, kidney and heart. Presented at: American Heart Association Scientific Sessions; Nov. 13-17, 2020 (virtual meeting).
Disclosures:
Filippatos reports he receives lecture or advisory board fees from Amgen, Bayer, Boehringer Ingelheim, Medtronic, Novartis, Servier and Vifor. Wanner reports he receives lecture or advisory fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, FMC, Gilead, GlaxoSmithKline and…
Continue Reading
